Titan Pharmaceuticals, Inc.
TTNP
$4.38
-$0.07-1.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 534.00K | 666.00K | 754.00K | 2.07M | 1.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 534.00K | 666.00K | 754.00K | 2.07M | 1.06M |
| Operating Income | -534.00K | -666.00K | -754.00K | -2.07M | -1.06M |
| Income Before Tax | -563.00K | -790.00K | -763.00K | -2.09M | -1.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -563.00K | -790.00K | -763.00K | -2.09M | -1.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -563.00K | -790.00K | -763.00K | -2.09M | -1.06M |
| EBIT | -534.00K | -666.00K | -754.00K | -2.07M | -1.06M |
| EBITDA | -532.80K | -666.00K | -754.00K | -2.07M | -1.06M |
| EPS Basic | -0.62 | -0.86 | -0.83 | -2.29 | -1.24 |
| Normalized Basic EPS | -0.39 | -0.54 | -0.52 | -1.43 | -0.78 |
| EPS Diluted | -0.62 | -0.86 | -0.83 | -2.29 | -1.24 |
| Normalized Diluted EPS | -0.39 | -0.54 | -0.52 | -1.43 | -0.78 |
| Average Basic Shares Outstanding | 914.00K | 914.00K | 914.00K | 914.00K | 853.00K |
| Average Diluted Shares Outstanding | 914.00K | 914.00K | 914.00K | 914.00K | 853.00K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |